Financhill
Back

Revance Therapeutics Quote, Financials, Valuation and Earnings

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade
Sell
13

RVNC
Revance Therapeutics

Last Price:
3.71
Seasonality Move:
7.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!

Revance Therapeutics Price Quote

$3.71
+0.00 (+-35.81%)
(Updated: November 9, 2024 at 5:44 AM ET)

Revance Therapeutics Key Stats

Sell
13
Revance Therapeutics (RVNC) is a Sell

Day range:
$3.48 - $4.34
52-week range:
$2.30 - $9.75
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.40
P/B ratio:
0%

Volume:
13M
Avg. volume:
2M
1-year change:
-55.52%
Market cap:
$386M
Revenue:
$234M
EPS:
$-3.2

How Much Does Revance Therapeutics Make?

Is Revance Therapeutics Growing As A Company?

  • What Is Revance Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.2%
  • What Is Revance Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Revance Therapeutics Stock Price Performance

What Is Revance Therapeutics 52-Week High & Low?

Revance Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Revance Therapeutics?

Is Revance Therapeutics Cash Flow Positive?

  • What Is RVNC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$200.8M
  • What Is Revance Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $125.2M
  • What Is Revance Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $15.4M

Revance Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    RVNC return on invested capital is -87.72%
  • What Is Revance Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -55.05%
  • What Is RVNC Return On Equity?
    ROE is a measure of profitability and is 0%

Revance Therapeutics Earnings Date & Stock Price

Revance Therapeutics Competitors

Revance Therapeutics Dividend Yield

Revance Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 6.33%
Revenue: 20.17% -12.17%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 8
Sell Recommendations: 0
Price Target: 9.23
Upside from Last Price: 149.01%

Major Shareholders

  • How many RVNC shares are owned by institutional investors?
    124.5M RVNC shares are owned by institutional investors
  • How many RVNC shares are owned by insiders?
    2.7M RVNC shares are owned by insiders